Related Experiment Video
Updated: Jul 14, 2026
08:48
Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis
Published on: March 19, 2019
Anidulafungin versus fluconazole for invasive candidiasis
Annette C Reboli1, Coleman Rotstein, Peter G Pappas
1University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and Cooper University Hospital, Camden, NJ 08103, USA. reboli-annette@cooperhealth.edu
The New England Journal of Medicine
|June 15, 2007
Summary
Anidulafungin demonstrated noninferiority to fluconazole for invasive candidiasis treatment. This echinocandin showed higher success rates and a trend towards lower mortality in a randomized trial.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Trials
Background:
- Anidulafungin is an echinocandin with potent activity against Candida species.
- Invasive candidiasis is a serious fungal infection requiring effective treatment.
Purpose of the Study:
- To compare the efficacy and safety of anidulafungin versus fluconazole for treating invasive candidiasis.
- To establish noninferiority of anidulafungin to fluconazole.
Main Methods:
- A randomized, double-blind, noninferiority trial involving 245 adults with invasive candidiasis.
- Patients received either intravenous anidulafungin or intravenous fluconazole, with options for oral fluconazole after 10 days.
- Primary efficacy assessed global response (clinical and microbiologic) at the end of intravenous therapy.
Main Results:
- Anidulafungin achieved a higher treatment success rate (75.6%) compared to fluconazole (60.2%) at the end of intravenous therapy.
- Adverse events were similar between groups, but the all-cause mortality rate was lower in the anidulafungin group (23% vs. 31%).
- No significant center effect was observed in the efficacy analysis.
Conclusions:
- Anidulafungin is noninferior to fluconazole for treating invasive candidiasis.
- Anidulafungin presents a viable alternative treatment option with a favorable safety profile and a trend towards improved survival.
Related Concept Videos
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...